NAD dismisses Zicam case
This article was originally published in The Tan Sheet
Executive Summary
Quigley's use of Gel Tech's submissions to NAD as evidence in its federal court proceeding against Zicam has caused the Council of Better Business Bureaus' National Advertising Division to close its review of Gel Tech's ad claims for Zicam Cold Remedy without issuing a decision. Quigley, the marketer of Cold-Eeze lozenges and challenger of the Zicam claims, violated their confidentiality agreement through its actions, NAD says (1"The Tan Sheet" April 24, p. 8). NAD notes it had "concerns" about whether the claims, including "highly effective cold remedy" and "reduce the duration of the common cold," were adequately supported